iShares Biotechnology ETF
278 hedge funds and large institutions have $3.12B invested in iShares Biotechnology ETF in 2013 Q4 according to their latest regulatory filings, with 54 funds opening new positions, 89 increasing their positions, 94 reducing their positions, and 26 closing their positions.
108% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 26
58% more funds holding in top 10
Funds holding in top 10: 12 → 19 (+7)
24% more capital invested
Capital invested by funds: $2.51B → $3.12B (+$606M)
10% more funds holding
Funds holding: 253 → 278 (+25)
5% less repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 94
60% less call options, than puts
Call options by funds: $177M | Put options by funds: $443M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$192M |
| 2 |
Citigroup
New York
|
+$161M |
| 3 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
+$68.7M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$49.2M |
| 5 |
Canada Life
Winnipeg,
Manitoba, Canada
|
+$22.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Allianz Asset Management
Munich,
Germany
|
-$115M |
| 2 |
DC
Davenport & Co
Richmond,
Virginia
|
-$47.2M |
| 3 |
Neuberger Berman Group
New York
|
-$31.2M |
| 4 |
Barclays
London,
United Kingdom
|
-$17.1M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$9.52M |
IBB Hedge Fund Activity: Q4 2013 in Review
278 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q4 2013, worth a combined $3.12B — up 24% from $2.51B a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new IBB positions and 26 closed out — a net gain of 28 holders — while 89 added to existing stakes and 94 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $192M. The largest seller was Allianz Asset Management, exiting entirely with an estimated $115M sold.
- 278 institutional investors held iShares Biotechnology ETF (IBB) as of Q4 2013, up from 253 in Q3 2013.
- Funds reported $3.12B of iShares Biotechnology ETF stock for Q4 2013, up 24% quarter-over-quarter.
- 54 funds opened new iShares Biotechnology ETF positions in Q4 2013 and 26 closed out, a net change of +28 holders.
- The largest iShares Biotechnology ETF buyer in Q4 2013 was Goldman Sachs, an estimated $192M added.
- The largest iShares Biotechnology ETF seller in Q4 2013 was Allianz Asset Management, an estimated $115M sold.
Based on aggregated 13F filings for Q4 2013.